Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile
Study: Erenumab Monotherapy Effective Long-Term For Episodic Migraines

Doctorpedia Editorial Team Doctorpedia Editorial Team
Medically reviewed by Susan Kerrigan, MD and Marianne Madsen

Many who suffer from episodic migraines (EM) have tried 2-4 preventive treatments and found them to be ineffective. However, results from the long-term extension of the LIBERTY study evaluating monthly erenumab monotherapy demonstrated continuous improvement on all efficacy outcomes in those who have not been responsive to 2-4 preventive migraine treatments.


Background on Erenumab 


Erenumab, a human monoclonal antibody, binds to the calcitonin gene-related peptide (CGRP) receptor to stop activation, contributing to fewer migraines. In previous randomized studies, Erenumab has proven to be safe and effective in EM and chronic migraines. While the results from the phase 3b trial, “Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (LIBERTY),” showed the efficacy of erenumab 140 mg in participants with EM who used 2-4 prior preventive treatments unsuccessfully, longer-term data was needed since adherence to preventive protocols is low. Health care professionals can use this information to talk with their patients about the importance of being consistent with their preventive therapy. Currently ongoing, results from the 3-year open-label extension phase (OLEP) of the LIBERTY study may also prove to be resourceful when published.

Clinical Trial Outcomes and Results


The researchers reported results based on participants who completed 64 weeks in the LIBERTY study and 52 weeks (1 year) of OLEP. Efficacy outcomes (OLEP) “included achievement of ≥50% reduction in monthly migraine days (MMD) compared to baseline, change in MMD from baseline, and change in everyday activities and physical impairment.” Researchers measured outcomes every month during the first 3 months and then the last month of each quarter through week 64.


Among the group of patients that continued with erenumab, the 50% responder rate improved from 29.9% at weeks 9-12 to 44.3% at weeks 61-64. In the OLEP, the 50% responder rate climbed from weeks 13-16 until weeks 37-40 and remained stable throughout weeks 61-64. Participants who started erenumab in the OLEP (switched from placebo during the double-blind treatment phase) showed continuous improvement from week 13 onward. The safety of erenumab was congruent with what was seen in prior clinical trials.


The data from year 1 of the 3-year OLEP of the LIBERTY study revealed consistent efficacy, a low dropout rate, and great tolerability.

Related Articles


Study: How Effective Is Erenumab in Preventing Migraine?

A new study shows that erenumab is helpful in treating headaches and migraine in patients by blocking a certain protein in the body.


COVID-19 & New-Onset Migraine and Tension-Type Headaches

A new study published in The Journal of Headache and Pain has aimed to examine the relationship between headaches and COVID-19.


Atogepant Shows Promise In Preventing Migraines

Atogepant, a prospective drug currently being developed by AbbVie, lowered migraine days in a recent study and showed optimistic results.

Send this to a friend